Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Hymel

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Molecules (Basel, Switzerland)|April 25, 2019
Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding InhibitorsXue Zhi Zhao, Kohei Tsuji, David Hymel, et al.
F1000Research|July 20, 2017
Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agentsJung-Eun Park, David Hymel, Terrence R Burke, et al.
Frontiers in Immunology|September 10, 2019
Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1Junpeng Qi, David Hymel, Christopher G Nelson, et al.
RSC Chemical Biology|September 21, 2022
Development of ultra-high affinity bivalent ligands targeting the polo-like kinase 1Kohei Tsuji, David Hymel, Buyong Ma, et al.
Bioorganic & Medicinal Chemistry Letters|September 4, 2018
Histidine N(τ)-cyclized macrocycles as a new genre of polo-like kinase 1 polo-box domain-binding inhibitorsDavid Hymel, Robert A Grant, Kohei Tsuji, et al.
Chemical Communications (Cambridge, England)|August 20, 2015
Fluorescent mimics of cholesterol that rapidly bind surfaces of living mammalian cellsDavid Hymel, Sutang Cai, Qi Sun, et al.
Angewandte Chemie (International Ed. in English)|April 25, 2020
Chemically Programmable and Switchable CAR-T TherapyJunpeng Qi, Kohei Tsuji, David Hymel, et al.
ACS Omega|August 29, 2019
Antibody-Drug Conjugate that Exhibits Synergistic Cytotoxicity with an Endosome-Disruptive PeptideKelsey E Knewtson, Chamani Perera, David Hymel, et al.
Diabetes Care|February 21, 2009
Lower total adipocyte number but no evidence for small adipocyte depletion in patients with type 2 diabetesMagdalena Pasarica, Hui Xie, David Hymel, et al.
Organic & Biomolecular Chemistry|August 4, 2021
Design and synthesis of a new orthogonally protected glutamic acid analog and its use in the preparation of high affinity polo-like kinase 1 polo-box domain - binding peptide macrocyclesDavid Hymel, Kohei Tsuji, Robert A Grant, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Molecules (Basel, Switzerland)|April 25, 2019
Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding InhibitorsXue Zhi Zhao, Kohei Tsuji, David Hymel, et al.
F1000Research|July 20, 2017
Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agentsJung-Eun Park, David Hymel, Terrence R Burke, et al.
Frontiers in Immunology|September 10, 2019
Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1Junpeng Qi, David Hymel, Christopher G Nelson, et al.
RSC Chemical Biology|September 21, 2022
Development of ultra-high affinity bivalent ligands targeting the polo-like kinase 1Kohei Tsuji, David Hymel, Buyong Ma, et al.
Bioorganic & Medicinal Chemistry Letters|September 4, 2018
Histidine N(τ)-cyclized macrocycles as a new genre of polo-like kinase 1 polo-box domain-binding inhibitorsDavid Hymel, Robert A Grant, Kohei Tsuji, et al.
Chemical Communications (Cambridge, England)|August 20, 2015
Fluorescent mimics of cholesterol that rapidly bind surfaces of living mammalian cellsDavid Hymel, Sutang Cai, Qi Sun, et al.
Angewandte Chemie (International Ed. in English)|April 25, 2020
Chemically Programmable and Switchable CAR-T TherapyJunpeng Qi, Kohei Tsuji, David Hymel, et al.
ACS Omega|August 29, 2019
Antibody-Drug Conjugate that Exhibits Synergistic Cytotoxicity with an Endosome-Disruptive PeptideKelsey E Knewtson, Chamani Perera, David Hymel, et al.
Diabetes Care|February 21, 2009
Lower total adipocyte number but no evidence for small adipocyte depletion in patients with type 2 diabetesMagdalena Pasarica, Hui Xie, David Hymel, et al.
Organic & Biomolecular Chemistry|August 4, 2021
Design and synthesis of a new orthogonally protected glutamic acid analog and its use in the preparation of high affinity polo-like kinase 1 polo-box domain - binding peptide macrocyclesDavid Hymel, Kohei Tsuji, Robert A Grant, et al.
Pageof 3